Ropivacaine is a newly introduced local anesthetic. No data are available regarding its safety, efficacy, or sensory-selectivity in children. The sciatic block duration and systemic toxicity of bupivacaine and ropivacaine were compared among infant, adolescent, and adult rats.


Infant, adolescent, and adult rats received blocks with ropivacaine or bupivacaine. Nociceptive, proprioceptive, and motor blockade were assessed. Systemic effects (contralateral leg analgesia, seizures, respiratory distress, apnea) were quantified. Plasma local anesthetic concentrations were measured at terminal apnea.


Nerve blockade for a given absolute dose lasted longer in infants than in older rats for both drugs. Block duration from ropivacaine generally was the same as or slightly shorter than bupivacaine. There was no difference in sensory-selectivity between the drugs. Doses required to induce all systemic toxicity indices were inversely related to age (e.g., the lethal dose in 50% of animals [LD50] of ropivacaine in infants is 155 mg/kg; in adults it is 54 mg/kg). All indices of toxicity occurred at higher doses per kilogram for ropivacaine than bupivacaine, at all ages (e.g., the LD50 of bupivacaine in infants is 92 mg/kg; in adults it is 30 mg/kg). Plasma concentrations at terminal apnea were higher for ropivacaine than for bupivacaine at all ages, and were higher in infants than in older rats.


Ropivacaine resembles bupivacaine in its local anesthetic effects but has a greater margin of safety. For a given absolute dose, sciatic blockade in infant rats lasts longer than in adolescents or adults. Although the doses (in milligrams per kilogram) causing toxicity were much higher in infants than in adults, this probably does not correspond to a wider therapeutic index.

This article is featured in “This Month in Anesthesiology.” Please see this issue of ANESTHESIOLOGY, page 9A.

Local anesthetics are used widely in children for topical topical and infiltration analgesia and for peripheral and central nerve blockade. Despite the excellent record of safety for these techniques, seizures and cardiovascular depression may occur with excessive doses or with inadvertent intravascular injection. [1-6] 

Ropivacaine is an amino-amide local anesthetic recently released for clinical use in the United States and many other countries. Studies in adult animals and in adult humans suggest that ropivacaine may have two advantages over bupivacaine:(1) It may have greater sensory-to-motor selectivity, and (2) it may be less cardiotoxic at equianesthetic doses and consequently have a wider margin of safety. No data in infant animals or children are available on the safety or efficacy of ropivacaine.

In adult humans, the relative potency of local anesthetics in producing mild systemic toxicity has been studied in volunteers receiving intravenous infusions until they report central nervous system symptoms or show electrocardiographic changes. [7]Such studies are unlikely to be performed in infants and younger children both because of ethical considerations and because of their more limited ability to report symptoms. Most of our information regarding systemic toxicity of local anesthetics in human infants and children is derived from case reports or clinical series reporting adverse events with particular doses or infusion rates. Studies in pigs [8]and sheep [9]have reported that infant animals are less susceptible than adult animals to the toxic effects of intravenously administered local anesthetics. However, there have been studies in dogs [10]that found the opposite trend with age, and there have been claims of increased susceptibility to cardiovascular and respiratory depression in human neonates. [11] 

We recently reported the development of an infant rat model to study the developmental aspects of local anesthetic action using percutaneous sciatic nerve blockade. [12]In the current study, we modified our previous model to compare the efficacy and toxicity of ropivacaine with those of bupivacaine. Specifically, we addressed the following questions:(1) How does the duration of sciatic nerve block from each drug compare in infant, adolescent, and adult rats?(2) Does one drug appear more sensory selective than the other in young or older rats?(3) How toxic is each drug in infant rats compared with adolescent or adult rats?

Stock Bupivacaine and Ropivacaine Solutions

Bupivacaine and ropivacaine hydrochloride (Astra USA, Westborough, MA) were obtained in 0.5% solutions and were diluted to the desired concentration in normal saline.

Animal Care

Animals were cared for in compliance with protocols approved by the Children's Hospital Animal Care and Use Committee. Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA). Rats are referred to as infants at 5 days of age, adolescents at 15 days, and adults at 70 days. Infant rats weighed 14 +/− 3 g (mean and standard deviation; n = 114), adolescents weighed 37 +/− 5 g (n = 96), and adults weighed 300 +/− 61 g (n = 104). They were housed in groups and kept in a 6 a.m. to 6 p.m. light-dark cycle. Rats were handled repeatedly by the investigators to diminish any effects of stress-induced analgesia. Infant and adolescent rats were separated from their mothers during testing but were promptly returned for warmth and food thereafter.

Sciatic Blockade Technique

Before nerve block injections were given, rats were anesthetized briefly with halothane by face mask. [12,13]General anesthesia lasted < 2 min. The block was conducted conducted by introducing a 30-gauge needle posteromedially to the greater trochanter, pointing in an anteromedial direction. [13,14]Once bone was contacted, the needle was withdrawn 1 mm and drug was injected. The left leg was always used for blocks; the right leg served as control. Investigators assessing neurobehavioral and toxic effects were blinded to the drugs and doses that each rat received.

Assessment of Nerve Blockade

The effectiveness of block was measured every 15 min in all rats, applying the methods of Thalhammer et al. [14]and Hu et al. [12], with some modifications [13]noted here. The sample size (n) for all experiments was 8-10 rats. The following modalities and functions were measured.

Nociceptive Block. Nociceptive block was tested in two ways. Mechanical nociception was assessed by pinching the lateral aspect of the plantar surface of the hindpaw for one second. All rats were treated with the same specified tool (medium pointed curved forceps, Fisher Scientific, Pittsburgh, PA) by the same investigator. Rats were scored as to whether they withdrew to pinch (score = 1) or did not withdraw (score = 0).

Thermal nociception was measured by a modified hot-plate test. [15]The time that a rat would leave its hindpaw on a hot plate (model 39D Hot Plate Analgesia Meter; IITC Inc., Woodland Hills, CA) at 56 [degree sign]C was measured using a stopwatch (this time is called thermal latency). The paw was removed from the hotplate after 12 s by the investigator to avoid harming the rat. This test was repeated three times on each hindpaw for each rat at every time point.

Positional Placing Response. The positional placing response is a test of proprioception. The hindpaw of each rat was pulled back with the dorsum touching the Table surface, and its response was scored as follows: 1 = the foot was returned to a position alongside its flank, with the claws splayed (normal); 2 = the foot was returned forward, but with the toes clubbed; 4 = the foot could not be returned (complete motor block). Any intermediate outcome was a score of 3. In infant rats, the score was 4 even in the unblocked state (consequently this test was not used as a measure of block efficacy in infants).

Extensor Postural Thrust. The extensor postural thrust is a measure of motor strength. The rat was held above a digital balance and allowed to bear weight on one hindpaw at a time. The maximum weight that the rat could bear without its ankle touching the balance was measured. In the 5-day-old rats, extensor postural thrust was scored as 0 or 1, depending on whether the rat could bear weight.

Hopping. Hopping tested several integrated functions. Each rat was suspended above a horizontal surface and was slowly moved laterally, with one foot touching the Table surface. The rat was scored (1 or 0) according to whether it could hop on that foot.

Analysis of Neurobehavioral Data

The duration of effective block for mechanical nociception for each rat was calculated as the mid-point between the last time when there was no response to pinch and the first time when there was a response to pinch. The duration of block of thermal nociception was the time required for latency to return to a value of 7 s (baseline latency is approximately 2 s; thus, 7 s represents the mid-point between maximal latency, which is set at a cutoff of 12 s, and baseline). Nociceptive data are also represented graphically (Figure 1) by averaging the latencies in a treatment group at different times after injection. The duration of block for the positional placing response was defined as the time that it took for the score to recover to a value of 2. The duration of block for hopping was the mid-point of the last time when the rat could not hop and the first time when it could. The duration of block for extensor postural thrust was defined as the time until 50% recovery of weight bearing.

Figure 1. The time course of thermal latency from sciatic nerve block with 0.1 ml 0.5% bupivacaine and ropivacaine in infant (5 days), adolescent (15 days), and adult (70 days) rats. Data points are mean latency +/− SD. n = 8 for each group.

Figure 1. The time course of thermal latency from sciatic nerve block with 0.1 ml 0.5% bupivacaine and ropivacaine in infant (5 days), adolescent (15 days), and adult (70 days) rats. Data points are mean latency +/− SD. n = 8 for each group.

Close modal

In all animals in which injection did not result in loss of pinch sensation, a thermal withdrawal latency of at least 7 s, a positional placing response score of 2 or more, a hopping score of 0, or at least a 50% reduction in weight-bearing in the extensor postural thrust test, the duration of effective block for the appropriate modality was considered 0 (zero) for computational purposes.

Toxicologic Indices and Determination of Plasma Concentration of Bupivacaine and Ropivacaine

Thermal latency was measured in the contralateral (uninjected) limb in all rats, as a measure of systemic toxicity. [13]Animals were scored as to whether they developed a latency of 12 s (score = 1) or not (score = 0). Seizures and respiratory distress were assessed as being either present (score = 1) or absent (score = 0) at any time. These clinical determinations were always made by the same observer. Seizures were diagnosed in rats displaying rapid, jerking, chaotic movements. These were not subtle and could not be confused with volitional movement of agitated rats. Respiratory distress was diagnosed in rats in which a pattern of slow deep breathing, gasping, or stertorous breathing developed.

Toxicity is expressed both graphically (milligrams of drug per kilogram shown on the x-axis; percentage of rats affected on the y-axis) and in terms of the dose per kilogram that affected 50% of rats (i.e., the ED50). The ED50(SZ), ED50(resp), ED50(lat), and the lethal dose that affected 50% of rats (LD50) are used for seizures, respiratory distress, the development of maximal latency (i.e., at 12 s) in the contralateral leg, and terminal apnea, respectively.

Rats that became apneic for 20 s received intraperitoneal pentobarbital before cardiac puncture and the aspiration of blood for determination of plasma drug levels. The whole blood was placed on ice immediately, and the plasma was separated by centrifugation within 30 min and stored at -20 [degree sign]C. Plasma concentrations of ropivacaine and bupivacaine were subsequently determined by gas chromatography as described. [16] 

Statistical Analysis

Durations of block and latencies in groups of rats are expressed as mean +/− SD. Most statistical inferences are made with the Student's t test (paired in comparisons between injected and contralateral legs, unpaired in all other cases), or with analysis of variance. In two instances (where adult rats were injected with 0.05 ml 0.1% bupivacaine or ropivacaine) the data were not normally distributed because of the presence of many zero-duration blocks. Here the results were reported as medians (25th to 75th percentiles). For comparisons involving these two data sets, we performed nonparametric tests (Kruskall-Wallis, Mann-Whitney U test, or both, or Wilcoxon matched-pairs signed-rank test). When multiple statistical comparisons were made between groups, Bonferroni correction was used; if n comparisons were made, a P value of 0.05/n was considered significant.

The LD50and effective concentration that affected 50% of rats values were calculated and compared using logit (logistic regression) analyses, using Stata statistical software (Stata Corporation, College Station, TX).

Effect of Age on the Duration of Thermal Nociceptive Block from Bupivacaine and Ropivacaine

Rats at 5 days (infants, 14 +/− 3 g), 15 days (adolescents, 37 +/− 5 g), and 70 days (adults, 300 +/− 61 g) were injected with bupivacaine or ropivacaine at a fixed dose (i.e., not scaled to body weight). Figure 1shows the time course of thermal latency for ropivacaine in all three ages (n = 8-10 in all neurobehavioral experiments). Analysis of the durations of thermal nociceptive block (Table 1) showed that the block lasted longer in infant rats than in adolescent or adult rats for both drugs at all dosages. At the higher volume of injectate (0.1 ml), there was no difference in the duration of block between adolescent and adult rats. However, when the volume was reduced to 0.05 ml, the duration of thermal nociceptive block was slightly longer in adolescents than in adult rats. At the lowest dosage (0.05 ml of 0.1% drug), where the difference between adolescents and adults was most striking, there were many (four of eight) zero-duration blocks in each of the adult groups.

Table 1. Duration (min) of Effective Block of Thermal Nociception with Bupivacaine and Ropivacaine

Table 1. Duration (min) of Effective Block of Thermal Nociception with Bupivacaine and Ropivacaine
Table 1. Duration (min) of Effective Block of Thermal Nociception with Bupivacaine and Ropivacaine

At most doses, there was little difference between the duration of block in adult and adolescent rats, despite a more than eightfold difference in weight. For example, the duration of thermal nociceptive block for 0.1 ml 0.5% ropivacaine was 107 +/− 10 min (mean +/− SD) for adult rats and 107 +/− 9 min for adolescent rats (P = 0.993). The duration of thermal nociceptive block in infants (179 +/− 22 min) was increased compared with that of adolescents (P < 0.0001) by approximately 70%. The average weight of infant rats was approximately 2.3 times less than adolescent rats.

Comparison of the Duration of Block from Bupivacaine and Ropivacaine

There was no significant difference in the duration of block between bupivacaine and ropivacaine at the higher dosage (0.1 ml 0.5% drug) at any age (Table 1). In the infant, there was no significant difference between the durations of thermal nociceptive block with bupivacaine and ropivacaine at any volume or concentration. With blocks performed using either lower volumes or more dilute concentrations in adolescents and adults, some comparisons showed a shorter duration of thermal nociceptive block with ropivacaine compared with bupivacaine (Table 1).

Functional Selectivity of Bupivacaine and Ropivacaine

We also evaluated the degree to which bupivacaine and ropivacaine affected the duration of block various functional modalities (Table 2). There were no significant differences between hotplate latency and any of the other four modalities (mechanical nociception, extensor positional thrust, hopping response, and positional placing response) when the higher doses (0.05 ml of 0.5% drug) were used in any of the age groups (top two sections of Table 2; data for adolescent rats not shown). The results were similar for rats injected with 0.1 ml 0.5% drug and 0.1 ml 0.1% drug (data not shown).

Table 2. Duration (min) of Effective Block from Bupivacaine or Ropivacaine for Each of the Functions Tested

Table 2. Duration (min) of Effective Block from Bupivacaine or Ropivacaine for Each of the Functions Tested
Table 2. Duration (min) of Effective Block from Bupivacaine or Ropivacaine for Each of the Functions Tested

It was possible that the lack of modality specificity was a result of the use of doses of local anesthetic high enough to fully block all fiber types regardless of their individual susceptibilities. To test this hypothesis, we compared the durations of block of the functional modalities at the lowest dose. In adult rats only that received 0.05 ml of 0.1% solution (bottom section of Table 2), the mean durations of the various modalities were different (Kruskall-Wallis test). Nevertheless, because of the low probability values required for statistical significance with multiple comparisons, we could not demonstrate differences in the duration of block for individual functions. Therefore, to the limits of detection by these measures, ropivacaine and bupivacaine were equally nonselective in their pattern of blockade.

(Figure 2) focuses on the clinically important comparison of the durations of motor block (extensor postural thrust; y-axis) and sensory block (thermal nociception; x-axis). There was no clear sensory selectivity (which would result in points below the diagonal line) for either drug at any dose.

Figure 2. A comparison of the durations of motor (extensor postural thrust) and sensory (thermal nociception) block for infant and adult rats receiving 0.05 ml 0.5% ropivacaine or bupivacaine, or 0.05 ml 0.1% drug ("low" dose in the figure). Data points are mean latency +/− SD, except for the low doses, which are median with 25th and 75th percentiles. The dotted line is a line of identity between nociceptive and motor blockade. n = 8-10 for each group.

Figure 2. A comparison of the durations of motor (extensor postural thrust) and sensory (thermal nociception) block for infant and adult rats receiving 0.05 ml 0.5% ropivacaine or bupivacaine, or 0.05 ml 0.1% drug ("low" dose in the figure). Data points are mean latency +/− SD, except for the low doses, which are median with 25th and 75th percentiles. The dotted line is a line of identity between nociceptive and motor blockade. n = 8-10 for each group.

Close modal

Toxicity of Bupivacaine and Ropivacaine

Groups of rats were injected at the sciatic nerve with increasing doses of bupivacaine or ropivacaine (scaled to body weight) and were observed for the development of (1) increased thermal latency in the contralateral (i.e., uninjected) extremity, (2) clinical seizures, (3) clinical respiratory distress, and (4) terminal apnea. Table 3tabulates the doses per kilogram at which 50% of rats were affected by each of these (ED50or LD50). All comparative statements made in the following description of those data assume that P < 0.01 is required for statistical significance.

Table 3. Doses (mg [middle dot] kg-1) of Bupivacaine and Ropivacaine Required to Induce Respiratory Distress, Increased Contralateral Latency, Seizures, or Terminal Apnea in 50% of Rats (ED50or LD50)

Table 3. Doses (mg [middle dot] kg-1) of Bupivacaine and Ropivacaine Required to Induce Respiratory Distress, Increased Contralateral Latency, Seizures, or Terminal Apnea in 50% of Rats (ED50or LD50)
Table 3. Doses (mg [middle dot] kg-1) of Bupivacaine and Ropivacaine Required to Induce Respiratory Distress, Increased Contralateral Latency, Seizures, or Terminal Apnea in 50% of Rats (ED50or LD50)

There was a consistent pattern of toxicity in all groups. The ED (50) s for the various indices generally occurred in the order ED50(resp) <or= to ED50(lat) <or= to ED50(sz) <or= to LD50(except in infants in which overt seizure activity was not seen in infant rats, possibly because respiratory arrest occurred first). This was true at all ages, and for both drugs.

Toxicity from both local anesthetics occurred at lower doses (scaled to body weight) in adults that in adolescents or infants. The LD50for bupivacaine was 30 +/− 5 mg/kg in adult rats, and 92 +/− 6 mg/kg in infant rats. Similarly, the LD50for ropivacaine was 56 +/− 6 mg/kg in adult rats, and 145 +/− 6 mg/kg in infants. For both drugs the onset of toxicity in infant rats was seen only at doses per kilogram exceeding doses per kilograms that would be universally toxic in adults (as evidenced by the fact that the ED50(resp) in infants was more than double the LD50in adults). The LD50s in adolescent rats were between the infant and adult values. For both drugs, the ED50s for the three other indices of toxicity, ED50(resp), ED50(lat), and ED50(sz), were also lowest in adults, were intermediate in adolescents, and were highest in infants. (It bears noting, however, that the absolute doses required to induce toxic end points were higher in adult than in infant rats. For example, the LD50s for ropivacaine in infant and adult rats were 145 mg/kg and 56 mg/kg, respectively, which corresponded to 2 mg and 16.8 mg, respectively.)

Ropivacaine was consistently less toxic than bupivacaine. The LD (50) s and all three ED50s were significantly higher for ropivacaine than for bupivacaine at all ages. In infant rats (Figure 3), the onset of overtly toxic effects occurred at a higher dose per kilogram of ropivacaine than the uniformly fatal dose per kilogram of bupivacaine: The ED50(resp) for ropivacaine was 116 +/− 6 mg/kg, whereas the LD95for bupivacaine was 103 +/− 11 mg/kg (P = 0.025). This impressive disparity between the toxic ranges of the two drugs was not seen to the same degree in the adult and adolescent rats.

Figure 3. The percentage of infant rats in which respiratory distress (the earliest sign of toxicity in our study) and terminal apnea developed with increasing doses of bupivacaine or ropivacaine.

Figure 3. The percentage of infant rats in which respiratory distress (the earliest sign of toxicity in our study) and terminal apnea developed with increasing doses of bupivacaine or ropivacaine.

Close modal

Plasma Concentrations of Ropivacaine or Bupivacaine at the Time of Terminal Apnea

Plasma was obtained from all rats that developed terminal apnea during the experiments, and the concentration of bupivacaine or ropivacaine was measured as described in Materials and Methods. The data were grouped by age and by drug (Table 4). The lethal concentration of ropivacaine was twice that of bupivacaine in adult rats, 2.5 times bupivacaine in adolescents, and 3.3 times bupivacaine in infant rats. The lethal serum concentrations of both drugs were significantly higher (Table 4) in infant rats than in adults (by a factor of approximately 1.5 for bupivacaine and 2 for ropivacaine) but they were not higher in adolescent compared with adult rats.

Table 4. Plasma Concentrations ([micro sign]g/ml) of Ropivacaine and Bupivacaine at Time of Terminal Apnea

Table 4. Plasma Concentrations ([micro sign]g/ml) of Ropivacaine and Bupivacaine at Time of Terminal Apnea
Table 4. Plasma Concentrations ([micro sign]g/ml) of Ropivacaine and Bupivacaine at Time of Terminal Apnea

Ropivacaine produced sciatic nerve blockade in infant, adolescent, and adult rats that appeared quite similar in duration and modality-selectivity to that seen with bupivacaine.

The duration of thermal nociceptive blockade from ropivacaine was not markedly different from bupivacaine at the higher dosages used, at any age. This is consistent with the findings of many investigators [17-25]in adult humans. Other investigators have found that the duration of blockade of ropivacaine is shorter than that of bupivacaine, [26-31]a pattern that also occurred in our study in adult and adolescent rats at the lower dosages.

We did not find significant differences in sensory versus motor block duration between the two drugs administered over a range of volumes and concentrations. Specifically, ropivacaine did not have a prolonged duration of sensory (thermal nociceptive) block compared with motor (extensor postural thrust) block. These data are consistent with the findings of some adult human studies, usually involving epidural anesthesia, [18,20,23,29,31,32]although other investigators have suggested that ropivacaine has a longer duration, frequency of sensory block, or both relative to motor block compared with bupivacaine. [17,19,21,22,24,26,28,30,33]Studies of ropivacaine and bupivacaine in brachial plexus block [23]and intercostal nerve block [29]did not show a relatively longer sensory block. Brachial plexus blockade in the guinea pig also did not show a relative prolongation of sensory over motor blockade. [25]The lack of sensory selectivity, in contrast to some human studies, may reflect at least three factors:(1) true species differences, (2) pharmacokinetic and pharmacodynamic differences between steady state prolonged epidural infusion versus single-shot peripheral blockade, and (3) greater precision of behaviorally based sensory and motor block measures in humans compared with rats.

Sciatic nerve blockade with both bupivacaine and ropivacaine lasted considerably longer in the infant than in the adolescent and adult rats when the same volume and concentration of drug (not scaled by body weight) was administered. At low doses, blockade in the adolescent was also longer than in adults, particularly with ropivacaine. The literature comparing the duration of regional anesthesia in adults and children is sparse, especially with respect to blockade outside the neuraxis, and most reports scale dosing with body weight. However, the duration of pediatric spinal anesthesia [34,35]has been reported to be shorter than in adults. Further, a recent study from this laboratory [12]showed that sciatic nerve block duration is shorter in infant than in adult rats, when doses are scaled by body weight.

Although the common clinical practice of scaling local anesthetics doses by weight in children makes sense from a toxicologic perspective, it is not clear that weight-based dosing is relevant for efficacy in nerve blockade. Our data showed constancy of block duration (or relatively small difference) when the same volume of drug was injected in adolescent and adult rats despite an eightfold difference in mass. (The only group in which there was a large difference between adults and adolescents was in the lowest dose group, in which the difference was largely accounted for by the larger number of unsuccessful blocks in the adults: Four of eight blocks were of zero duration for both bupivacaine and ropivacaine, whereas there were none in the adolescents. Our study could not distinguish between geometric, pharmacokinetic, and pharmacodynamic reasons for these unsuccessful blocks. Technical failure is an unlikely cause given the fact that these investigators consistently have success rates > 99% for obtaining block when larger doses are used.)

The toxicologic section of this study contains two principal findings. The first is that infants are much more resistant to the toxicity of bupivacaine and ropivacaine than are adolescents and adults on a dose-per-kilogram basis. The LD50(in milligrams per kilogram) in infants is three times the adult value for bupivacaine and 2.7 times the adult value for ropivacaine. Adolescent LD50s are also higher than in adults but less so (1.5 times for bupivacaine, 1.2 times for ropivacaine). The same is also true for the other manifestations of toxicity measured (ED (50rd) and ED501at). The plasma concentrations of both bupivacaine and ropivacaine at the time of terminal apnea were also higher in infants than in older rats. These findings are congruent with some previous research. Badgwell et al. [8]found that the doses of bupivacaine required to induce seizures, dysrhythmias, or both were higher in 2-day-old pigs than in 2-week-old or 2-month-old pigs. Further, the plasma concentrations of bupivacaine when those events occurred was higher in 2-day-old than in older pigs. However, unlike our findings, that study reported that the lethal dose (defined in mg/kg) was the same between the age groups. Morishima et al. [9]found that the dose that elicited convulsions from a lidocaine infusion was more than three times greater in newborn sheep than in adult animals, and they found similar differences in other measures of toxicity, such as hypotension and cardiovascular collapse. However, there is no universal agreement among laboratory investigations about the relative safety of ropivacaine versus bupivacaine. Riquelme et al. [10]found that 6-week-old dogs required a lower dose of bupivacaine than other ages to induce cardiovascular depression, and the plasma concentration that induced cardiovascular depression was lower in dogs younger than 13 weeks (inclusive) than in older dogs. (Interestingly, the mean toxic dose of bupivacaine in 2-week-old dogs was not lower than that of older dogs, and was possibly higher.) Our study provides further support of the view that infant animals are resistant to local anesthetic toxicity.

Although the LD50s for both local anesthetics in the infant rat is approximately three times the adult value in milligrams per kilogram, this should not be construed as indicating that the therapeutic index (LD50: ED50ratio) of either drug is greater in infants. If equal doses (in milligrams) are delivered to an infant or to an adult rat, the infant will receive 21.3 times as many milligrams per kilogram. Thus the therapeutic index in the infant rat is likely to be lower than in the adult (the local anesthetics would have to be 21.3/3 = 7.1 times more potent in the infant than in the adult for their therapeutic indices to be equal). We did not determine the ED50s of local anesthetics in this study, and therefore we cannot formally calculate the therapeutic index. Nonetheless, the conclusion that ropivacaine is safer in the infant than in the adult is probably not warranted.

The second finding was that at all ages, ropivacaine caused less toxicity than bupivacaine. The doses of ropivacaine required for toxicity or terminal apnea were typically approximately 1.5 times the corresponding doses of bupivacaine. In fact, in infants the first signs of toxicity from ropivacaine were encountered at doses that would have been uniformly lethal with bupivacaine. These findings are in accord with results reported in the current literature, in which ropivacaine was found to be safer than bupivacaine [17,25,26,28,36-38]in terms of neurologic and cardiovascular toxicity, and lethality. We also showed that the lethal plasma concentration of ropivacaine was significantly greater than that of bupivacaine at all ages. Thus the differences in LD50between ropivacaine and bupivacaine, and between infants and adults, are not solely the result of differences in uptake, distribution, and clearance, but rather appear to reflect intrinsic pharmacodynamic differences in toxicity or susceptibility.

In conclusion, we found little difference in efficacy and no difference in modality specificity between ropivacaine and bupivacaine. We also found that the duration of both drugs is longer in infants than in adults when equal volumes of the same drug concentrations are administered. However, there appears to be a much greater margin of safety with ropivacaine than bupivacaine, especially in infants. The data that we report here are the first demonstration of the safety of ropivacaine in an animal model of pediatric regional anesthesia and of its superior safety compared with bupivacaine. We believe these findings warrant further investigation in clinical comparisons of the two drugs in children.

The authors thank Randall Carpenter, of Astra USA, for encouragement and support.

Albright GA: Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51:285-7
Feldman HS, Arthur GR, Covino BG: Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog. Anesth Analg 1989; 69:794-801
Feldman HS, Arthur GR, Pitkanen M, Hurley R, Doucette AM, Covino BG: Treatment of acute systemic toxicity after the rapid intravenous injection of ropivacaine and bupivacaine in the conscious dog. Anesth Analg 1991; 73:373-84
Strichartz GR, Berde CB: Local Anesthetics, Anesthesia. Edited by RD Miller. New York, Churchill Livingstone, 1994, pp 489-521
Maxwell LG, Martin LD, Yaster M: Bupivacaine-induced cardiac toxicity in neonates: Successful treatment with intravenous phenytoin. Anesthesiology 1994; 80:682-6
Berde CB: Toxicity of local anesthetics in infants and children. J Pediatr 1993; 122:S14-20
Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundh R: Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69:563-9
Badgwell JM, Heavner JE, Kytta J: Bupivacaine toxicity in young pigs is age-dependent and is affected by volatile anesthetics. Anesthesiology 1990; 73:297-303
Morishima HO, Pedersen H, Finster M, Sakuma K, Bruce SL, Gutsche BB, Stark RI, Covino BG: Toxicity of lidocaine in adult, newborn, and fetal sheep. Anesthesiology 1981; 55:57-61
Riquelme CM, Bell B, Edwards J, Brown TCK: The influence of age on cardiovascular toxicity of intravenous bupivacaine in young dogs. Anaesth Intensive Care 1987; 15:436-9
Mirkin BL: Developmental pharmacology. Ann Rev Pharmacol 1970; 10:255-72
Hu D, Hu R, Berde CB: Neurologic evaluation of infant and adult rats before and after sciatic nerve blockade. Anesthesiology 1997; 86:957-65
Kohane DS, Yieh J, Lu NT, Langer R, Strichartz G, Berde CB: A re-examination of tetrodotoxin for prolonged anesthesia. Anesthesiology 1998; 89:119-31
Thalhammer JG, Vladimirova M, Bershadsky B, Strichartz GR: Neurologic evaluation of the rat during sciatic nerve block with lidocaine. Anesthesiology 1995; 82:1013-25
Masters DB, Berde CB, Dutta SK, Griggs CT, Hu D, Kupsky W, Langer R: Prolonged regional nerve blockade by controlled release of local anesthetic from a biodegradable polymer matrix. Anesthesiology 1993; 79:1-7
Bjork M: Capillary gas chromatographic method for the simultaneous determination of local anesthetics in plasma samples. J Chromatogr 1990; 533:229-34
Cederholm I: Preliminary risk-benefit analysis of ropivacaine in labour and following surgery. Drug Safety 1997; 16:391-402
McGlade DP, Kalpokas MV, Mooney PH, Buckland MR, Vallipuram SK, Hendrata MV, Torda TA: Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. Anaesth Intensive Care 1997; 25:262-6
Feldman HS, Dvoskin S, Arthur GR, Doucette AM: Antinociceptive and motor-blocking efficacy of ropivacaine and bupivacaine after epidural administration in the dog. Reg Anesth 1996; 21:318-26
Eddleston JM, Holland JJ, Griffin RP, Corbett A, Horsman EL, Reynolds F: A double-blind comparison of 0.25% ropivacaine and 0.25% bupivacaine for extradural analgesia in labour. Br J Anaesth 1996; 76:66-71
Griffin RP, Reynolds F: Extradural anaesthesia for caeserian section: A double-blind comparison of 0.5% bupivacaine. Br J Anaesth 1995; 74:512-6
Morrison LM, Emanuelsson BM, McClure JH, Pollok AJ, McKeown DW, Brockway M, Jozwiak H, Wildsmith JA: Efficacy and kinetics of extradural ropivacaine: Comparison with bupivacaine. Br J Anaesth 1994; 72:164-9
Hickey R, Rowley CL, Candido KD, Hoffman J, Ramamurthy S, Winnie AP: A comparative study of 0.25% ropivacaine and 0.25% bupivacaine for brachial plexus block. Anesth Analg 1992; 75:602-6
Kerkkamp HE, Gielen MJ, Edstrom HH: Comparison of 0.75% ropivacaine with epinephrine and 0.75% bupivacaine with epinephrine in lumbar epidural anesthesia. Reg Anesth 1990; 15:204-7
Akerman B, Hellberg I-B, Trossvik C: Primary evaluation of the local anaesthetic properties of the amino amide agent ropivacaine (LEA 103). Acta Anaesthesiol Scand 1988; 32:571-8
Markham A, Faulds D: Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs 1996; 52:429-49
Tuttle AA, Katz JA, Bridenbaugh PO, Quinlan R, Knarr D: A double-blind comparison of the abdominal wall relaxation produced by epidural 0.75% ropivacaine and 0.75% bupivacaine in gynecologic surgery. Reg Anesth 1995; 20:515-20
de Jong RH: Ropivacaine. White knight or dark horse? Reg Anesth 1995; 20:474-81
Kopacz DJ, Emanuelsson BM, Thompson GE, Carpenter RL, Stephenson CA: Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. Anesthesiology 1994; 81:1139-48
Brockway MS, Bannister J, McClure JH, McKeown D, Wildsmith JA: Comparison of extradural ropivacaine and bupivacaine. Br J Anaesth 1991; 66:31-7
Brown DL, Carpenter RL, Thompson GE: Comparison of 0.5% ropivacaine and 0.5% bupivacaine for epidural anesthesia in patients undergoing lower-extremity surgery. Anesthesiology 1990; 72:633-6
McCrae AF, Jozwiak H, McClure JH: Comparison of ropivacaine and bupivacaine in extradural analgesia for the relief of pain in labour. Br J Anaesth 1995; 74:261-5
Zaric D, Nydahl PA, Philipson PA, Samuelsson L, Heierson A, Axelsson K: The effect of continuous lumbar epidural infusion of ropivacaine (0.1%, 0.2%, and 0.3%) and 0.25% bupivacaine on sensory and motor block in volunteers: A double-blind study. Reg Anesth 1996; 21:14-25
Dohi S, Naito H, Takahashi T: Age-related changes in blood pressure and duration of motor block in spinal anesthesia. Anesthesiology 1979; 50:319-23
Abajian J, Mellish R, Browne A, Perkins F, Lambert D, Mazuzan JJ: Spinal anesthesia for surgery in the high-risk infant. Anesth Analg 1984; 63:359-62
Reiz S, Haggmark S, Johansson G, Nath S: Cardiotoxicity of ropivacaine-A new amide local anesthetic agent. Acta Anesthesiol Scand 1989; 33:93-8
Moller R, Covino BG: Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic. Anesthesiology 1990; 72:322-9
Santos AC, Arthur GR, Wlody D, De Armas P, Morishima HO, Finster M: Comparative systemic toxicity of ropivacaine in nonpregnant and pregnant ewes. Anesthesiology 1995; 82:734-40